Dual vs Triple Anti-Thrombotic Therapy for Post-PCI Patients With Atrial Fibrillation
Published: 21 May 2020
- Discuss and debate the four major trials in the DOAC space for post PCI patients with atrial fibrillation in light of international guidelines
- Review the differences in the study designs and aspirin cut-offs and the implications on the data
- Discuss and analyse the role of aspirin in the treatment of anti-thrombotic post PCI for patients with Atrial Fibrillation and ACS
- Analyse and debate the impact on patient care
Scope of the Problem and Key Challenges
Evolution of the Data – the Trials and the Differences
Senior Consultant in Electrophysiology and Devices
Professor Jan Steffel is a Cardiologist and Senior Consultant in Electrophysiology and Devices at the Hirslanden Clinic in Zurich and Professor of Cardiology at the University of Zurich.
He has over 150 publications in international and national journals and is board-certified in Internal Medicine and Cardiology. He was Associate Editor for the European Heart Journal from 2012 and became Deputy Editor in 2017. He is a member of the Foederatio Medicorum Helveticorum (FMH), Swiss Society for General Internal Medicine (SGAIM), Swiss Society for Cardiology (SGK) and European Society of Cardiology (ESC).
Jur ten Berg
Prof Jur ten Berg is Head of the St Antonius Center for Platelet Function Studies at the St Antonius Hospital, The Netherlands, where he also serves as Director of the Cardiology Training Programme. He has published over 400 peer-reviewed articles.
Stefan H Hohnloser
Professor of Medicine and Cardiology
Stefan H Hohnloser is Professor of Medicine and Cardiology at the Johann Wolfgang Goethe University in Frankfurt, Germany, where he is the Head of the Department of Electrophysiology. His primary research interests include sudden cardiac death and its prevention by device therapy.